SYNAGIS is contraindicated in patients with known hypersensitivity to palivizumab or to any of its excipients. It is also contraindicated in patients with known hypersensitivity to other humanized monoclonal antibodies.
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.